Patents by Inventor Miho Shinmura

Miho Shinmura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Type A2 botulinum toxin preparation
    Patent number: 9623075
    Abstract: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: April 18, 2017
    Assignee: THE CHEMO-SERO THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Shinji Nakahira, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Satomi Munechika, Sachio Okuda, Shunji Kozaki
  • Highly purified type A toxin preparation from infant botulism pathogen
    Patent number: 9278133
    Abstract: A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional known botulinum toxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: March 8, 2016
    Assignees: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, TOKUSHIMA UNIVERSITY
    Inventors: Tetsuhiro Harakawa, Hirotoshi Nakano, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Sachio Okuda, Ryuji Kaji, Shunji Kosaki
  • TYPE A2 BOTULINUM TOXIN PREPARATION
    Publication number: 20130252902
    Abstract: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.
    Type: Application
    Filed: May 28, 2013
    Publication date: September 26, 2013
    Applicant: THE CHEMO-SERO THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Shinji NAKAHIRA, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Satomi Munechika, Sachio Okuda, Shunji Kozaki
  • TYPE A2 BOTULINUM TOXIN PREPARATION
    Publication number: 20110033431
    Abstract: A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a botulinum toxin from type A1 Clostridium botulinum (type A1 botulinum toxin), said preparation comprising as an active ingredient 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX); a medicament for treating a disease with muscle overactivity for use in a patient who has a neutralizing antibody to a type A1 botulinum toxin, said medicament comprising as an active ingredient said A2 NTX; a method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering said A2 NTX to the patient; and a method for use of A2 NTX in a patient who has said neutralizing antibody. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation comprising a type A1 botulinum toxin.
    Type: Application
    Filed: March 31, 2009
    Publication date: February 10, 2011
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Shinji Nakahira, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Satomi Munechika, Sachio Okuda, Shunji Kozaki
  • Highly Purified Type A Botulinum Toxin Preparation From Infant Botulism Pathogen
    Publication number: 20100173841
    Abstract: A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional known botulinum toxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.
    Type: Application
    Filed: October 26, 2007
    Publication date: July 8, 2010
    Applicant: Juridical Foundation the Chemo-Sero-Therapeutic Research Institute
    Inventors: Tetsuhiro Harakawa, Hirotoshi Nakano, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Sachio Okuda, Ryuji Kaji, Shunji Kosaki